OT-730

Details

Stereochemistry	EPIMERIC
Molecular Formula	C25H36N2O8
Molecular Weight	492.5619
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC(O)=C(O)C=C1C(=O)OC[C@H](CNC(C)(C)CNC(=O)C2CCOC2)OC(=O)C3(C)CC3

InChI

InChIKey=ANXXSWNMHQHOQC-DJNXLDHESA-N

InChI=1S/C25H36N2O8/c1-15-9-19(28)20(29)10-18(15)22(31)34-13-17(35-23(32)25(4)6-7-25)11-27-24(2,3)14-26-21(30)16-5-8-33-12-16/h9-10,16-17,27-29H,5-8,11-14H2,1-4H3,(H,26,30)/t16?,17-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C25H36N2O8
Molecular Weight	492.5619
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	1 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:32:08 UTC 2023` Edited by `admin` on `Sat Dec 16 11:32:08 UTC 2023`
Record UNII	5WVS67PLAL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OT-730

Common Name

English

OT 730

Code

English

((2S)-3-((1,1-DIMETHYL-2-(TETRAHYDROFURAN-3-CARBONYLAMINO)ETHYL)AMINO)-2-(1-METHYLCYCLOPROPANECARBONYL)OXY-PROPYL) 4,5-DIHYDROXY-2-METHYL-BENZOATE

Systematic Name

English

QLT-091568

Code

English

BENZOIC ACID, 4,5-DIHYDROXY-2-METHYL-, (2S)-3-((1,1-DIMETHYL-2-(((TETRAHYDRO-3-FURANYL)CARBONYL)AMINO)ETHYL)AMINO)-2-(((1-METHYLCYCLOPROPYL)CARBONYL)OXY)PROPYL ESTER

Systematic Name

English

Code System Code Type Description

FDA UNII

5WVS67PLAL

Created by admin on Sat Dec 16 11:32:08 UTC 2023 , Edited by admin on Sat Dec 16 11:32:08 UTC 2023

PRIMARY

CLINICAL_TRIALS.GOV

OT-730

Created by admin on Sat Dec 16 11:32:08 UTC 2023 , Edited by admin on Sat Dec 16 11:32:08 UTC 2023

PRIMARY

The purpose of this study is to evaluate the safety and potential efficacy of a new drug, OT-730 ophthalmic solution (eye drops), in reducing intraocular pressure in the eyes of patients with open angle glaucoma or ocular hypertension. It will be compared with commercial timolol and placebo eye drops.

CAS

870809-51-1

Created by admin on Sat Dec 16 11:32:08 UTC 2023 , Edited by admin on Sat Dec 16 11:32:08 UTC 2023

PRIMARY

PUBCHEM

11554979

Created by admin on Sat Dec 16 11:32:08 UTC 2023 , Edited by admin on Sat Dec 16 11:32:08 UTC 2023

PRIMARY

Related Record Type Details


					5WVS67PLAL

OT-730

ACTIVE MOIETY

Comments:

Class: Anti-glaucoma, Anti-hyper-tensive, Small molecule; Mechanism of Action: Beta-adrenergic receptor antagonist; Highest Development Phase: Discontinued for Glaucoma, Ocular hypertension; Most Recent Events: 03 Nov 2010 Discontinued - Phase-I/II for Glaucoma in USA (Ophthalmic), 30 Dec 2009 QLT acquires OT 730 from Othera Pharmaceuticals, 19 Sep 2008 Phase-I/II clinical trials in Glaucoma in USA (Ophthalmic)


					5WVS67PLAL

OT-730

ACTIVE MOIETY

Comments:

Development Status and FDA Approval Process for OT-730: OT-730 is a novel, internally developed next generation topical beta-blocker designed to lower intra-ocular pressure (IOP), the leading risk factor for developing glaucoma.